Rigel Pharmaceuticals Inc. (Nasdaq: RIGL) reported disappointing results from a FIT Phase 3 clinical program for fostamatinib sending the stock price down 49 cents to close at $2.73.
Rigel Pharmaceuticals reports disappointing study results
October 20, 2016 at 17:16 PM EDT
